
The Canadian Government has signed a multi-year contract with Bavarian Nordic for supplies of its monkeypox vaccine. The contract has an estimated value of USD 56m.
Bavarian Nordic’s vaccine is approved for both smallpox and monkeypox in the country, where it is marketed under the name Imvamune. Canada is the only country other than the US where it is authorized in both indications.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app